8-K: Finch Therapeutics to Delist from Nasdaq and Deregister with SEC

Finch Therapeutics has announced its decision to delist from the Nasdaq and deregister its common stock with the SEC, citing cost savings and compliance burdens.

Summary

• Finch Therapeutics has decided to delist its common stock from the Nasdaq Global Select Market.
• The company will file a Form 25 with the SEC on or about October 31, 2024, to initiate the delisting process.
• The delisting will become effective 10 days after the Form 25 filing.
• Finch also intends to deregister its common stock under the Securities Exchange Act of 1934, which is expected to occur 90 days after the Form 25 filing.
• Following delisting, the company plans to file a Form 15 with the SEC on or about November 11, 2024, to suspend its reporting obligations.
• The company's stock has been trading on the OTC market since May 28, 2024, after being suspended from Nasdaq due to a public shell determination.
• Finch expects its stock to continue trading on the OTC market after delisting, but there are no guarantees.
• The decision to delist and deregister was made to reduce costs associated with SEC reporting and compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting from Nasdaq, which is generally seen as a sign of financial distress or strategic shift away from public markets. While cost savings are a positive, the loss of exchange listing is a significant negative.

Positives

• The delisting and deregistration are expected to reduce significant costs associated with SEC reporting and compliance.
• The company will save on legal, audit, and other expenses related to being a reporting company.
• Management's time will be freed up from the demands of the Sarbanes-Oxley Act, SEC rules, and Nasdaq listing standards.

Negatives

• The company's stock will no longer be listed on the Nasdaq Global Select Market.
• There is no guarantee that trading of the common stock on the OTC market will be maintained.
• The company will no longer be required to file periodic reports with the SEC, reducing transparency.

Risks

• The delisting and deregistration process may take longer than expected.
• The benefits of delisting and deregistration may not be fully realized.
• There is a risk that trading on the OTC market may not be maintained.
• Changes in laws and regulations could impact the company's plans.

Future Outlook

The company expects its common stock to continue trading on the OTC market after delisting, but there are no guarantees. The company aims to realize the value of its intellectual property through licensing and litigation.

Management Comments

• The Board determined that delisting and deregistration is in the best interest of the Company and the holders of its Common Stock.
• The decision was based on a careful review of numerous factors, including the potential for limiting the significant costs associated with preparing and filing periodic reports with the SEC.

Industry Context

This announcement reflects a trend of companies seeking to reduce costs and compliance burdens by delisting from major exchanges, particularly when facing challenges in meeting listing requirements. It also highlights the challenges faced by smaller biotech companies in maintaining compliance with stringent regulations.

Comparison to Industry Standards

• Many small biotech companies face challenges in maintaining Nasdaq listing compliance due to market capitalization requirements and the costs associated with SEC reporting.
• Delisting and moving to the OTC market is a common strategy for companies seeking to reduce costs and compliance burdens.
• Companies like Finch, with a focus on intellectual property, may find it more cost-effective to pursue licensing and litigation strategies rather than maintaining a public listing.

Stakeholder Impact

• Shareholders will see their stock delisted from Nasdaq, potentially impacting liquidity and valuation.
• Employees may experience uncertainty due to the company's strategic shift.
• Customers and partners may be affected by the company's reduced public profile.

Next Steps

• File Form 25 with the SEC on or about October 31, 2024.
• Delist from Nasdaq 10 days after the Form 25 filing.
• Deregister common stock under the Exchange Act 90 days after the Form 25 filing.
• File Form 15 with the SEC on or about November 11, 2024.
• Continue trading on the OTC market.

Key Dates

Keywords

delisting, deregistration, Nasdaq, SEC, OTC, common stock, reporting obligations, Form 25, Form 15, public shell, microbiome technology